Prospective Evaluation of the Strategy of Functionally Optimized Coronary Intervention.
Aged
Cardiac Catheterization
Coronary Angiography
Coronary Artery Disease
/ diagnosis
Coronary Vessels
/ diagnostic imaging
Feasibility Studies
Fractional Flow Reserve, Myocardial
Humans
Male
Middle Aged
Percutaneous Coronary Intervention
/ adverse effects
Predictive Value of Tests
Prospective Studies
Registries
Stents
Time Factors
Treatment Outcome
coronary revascularization
coronary stenting
fractional flow reserve
functional coronary intervention
ischemia
percutaneous coronary intervention
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
04 02 2020
04 02 2020
Historique:
entrez:
5
2
2020
pubmed:
6
2
2020
medline:
22
12
2020
Statut:
ppublish
Résumé
Background Long-term outcomes after percutaneous coronary intervention (PCI) relate in part to residual ischemia in the treated vessel, as reflected by post-PCI fractional flow reserve (FFR). The strategy of FFR after PCI and treatment of residual ischemia-known as functionally optimized coronary intervention (FCI)-may be feasible and capable of improving outcomes. Methods and Results Feasibility and results of FCI using an optical-sensor pressure wire were prospectively evaluated in an all-comer population with 50% to 99% lesions and ischemic FFR (≤0.80; ClinicalTrials.gov identifier NCT03227588). FCI was attempted in 250 vessels in 226 consecutive patients. The PCI success rate was 99.6% (249/250 vessels). FCI technical success-that is, FFR before and after PCI and PCI itself using the FFR wire-was 92% (230/250 vessels). Incidence of residual ischemia in the treated vessel was 36.5%. Approximately a third of these vessels (34.5%, n=29) were considered appropriate for further intervention, with FFR increasing from 0.71±0.07 to 0.81±0.06 (
Identifiants
pubmed: 32013707
doi: 10.1161/JAHA.119.015073
pmc: PMC7033880
doi:
Banques de données
ClinicalTrials.gov
['NCT03227588']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e015073Références
J Am Coll Cardiol. 2019 Feb 19;73(6):629-638
pubmed: 30428398
Lancet. 2015 Nov 7;386(10006):1853-60
pubmed: 26333474
Circ Cardiovasc Interv. 2019 Feb;12(2):e007030
pubmed: 30732469
JACC Cardiovasc Interv. 2011 Nov;4(11):1183-9
pubmed: 22115657
JACC Cardiovasc Interv. 2017 May 22;10(10):986-995
pubmed: 28456699
J Clin Epidemiol. 1995 Dec;48(12):1503-10
pubmed: 8543964
Circ Cardiovasc Interv. 2019 Feb;12(2):e007718
pubmed: 30732470
Cardiovasc Interv Ther. 2016 Jan;31(1):29-37
pubmed: 26135607
J Am Heart Assoc. 2020 Feb 4;9(3):e015073
pubmed: 32013707
JACC Cardiovasc Interv. 2018 Oct 22;11(20):2099-2109
pubmed: 30336814
N Engl J Med. 2012 Sep 13;367(11):991-1001
pubmed: 22924638
Circulation. 2019 Jan 29;139(5):694-706
pubmed: 30689413
Circulation. 2002 Jun 25;105(25):2950-4
pubmed: 12081986
Am Heart J. 2017 Feb;184:10-16
pubmed: 27892882
Circ Cardiovasc Interv. 2017 Oct;10(10):
pubmed: 29038228
J Am Coll Cardiol. 2014 Oct 21;64(16):1641-54
pubmed: 25323250
N Engl J Med. 1979 Jul 12;301(2):61-8
pubmed: 449946
JACC Cardiovasc Interv. 2016 May 23;9(10):1022-31
pubmed: 27198682
JACC Cardiovasc Interv. 2009 Apr;2(4):357-63
pubmed: 19463450
J Am Coll Cardiol. 2017 Dec 26;70(25):3088-3096
pubmed: 29268922
J Am Coll Cardiol. 2018 Dec 18;72(24):3126-3137
pubmed: 30261237
Circ Cardiovasc Interv. 2017 Aug;10(8):
pubmed: 28790165
EuroIntervention. 2018 Dec 20;14(12):e1324-e1331
pubmed: 29784630